The Financial Times quoted people familiar with the matter as saying that Moderna had refused to hand over to China the basic intellectual property rights behind developing a Covid-19 vaccine, which led to the breakdown of negotiations over its sale there.
The newspaper, quoting people involved in negotiations between 2020 and 2021, said that the Cambridge-based pharmaceutical company in the US state of Massachusetts refused China’s request to deliver its vaccine prescription due to commercial and safety concerns. She added that the company was still “keen” to sell the vaccine to China.
Moderna did not immediately respond to a Reuters request for comment. China has not approved any foreign vaccines for COVID-19 and relies on many domestically developed vaccines.
In September, Moderna’s chief medical officer, Paul Burton, said the company was keen to cooperate with China to supply the country with RNA-based COVID-19 vaccines.